当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2016年第31期
编号:12986287
过氧化物酶增殖物激活受体γ在分化型甲状腺癌中的表达及临床意义(4)
http://www.100md.com 2016年11月5日 《中国医药导报》 2016年第31期
     [15] Kato Y,Ying H,Zhao L,et al. PPAR[gamma] insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-[kappa] B signaling pathway [J]. Oncogene,2006,25(19):2736-2747.

    [16] Wood WM,Sharma V,Bauerle KT,et al. PPARgamma promotes growth and invasion of thyroid cancer cells [J]. Ppar Research,2011,2011(5):1-11.

    [17] Kroll TG,Sarraf P,Pecciarini L,et al. PAX8-PPAR-γ1 fusion in oncogene human thyroid carcinoma [J]. Science,2000,289(5483):1357-1360.

    [18] Giordano TJ,Au AY,Kuick R,et al. Delineation,functional validation,and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation [J]. Clin Cancer Res,2006,12(7 Pt 1):1983-1993.

    [19] Vanden Heuvel JP. Peroxisome proliferator-activated receptors:a critical link among fatty acids,gene expression and carcinogenesis [J]. Journal of Nutrition,1999,129(2S Suppl):575S-580S.

    [20] Castro P,Rebocho AP,Soares RJ,et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma [J]. Journal of Clinical Endocrinology & Metabolism,2006,91(91):213-220.

    (收稿日期:2016-07-14 本文編辑:张瑜杰), http://www.100md.com(茹晓婷 刘勤江 杨荣)
上一页1 2 3 4